LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 26

Search options

  1. Article ; Online: Characterizing user demographics in posts related to breast, lung and colon cancer on Japanese twitter (X).

    Kusudo, Maho / Terada, Mitsuo / Kureyama, Nari / Wanifuchi-Endo, Yumi / Fujita, Takashi / Asano, Tomoko / Kato, Akiko / Mori, Makiko / Horisawa, Nanae / Toyama, Tatsuya

    Scientific reports

    2024  Volume 14, Issue 1, Page(s) 6485

    Abstract: Various cancer-related information is spreading on social media. Our study aimed to examine the account types associated with cancer-related tweets (currently known as posts) on Twitter (currently known as X) in Japan, specifically focusing on breast, ... ...

    Abstract Various cancer-related information is spreading on social media. Our study aimed to examine the account types associated with cancer-related tweets (currently known as posts) on Twitter (currently known as X) in Japan, specifically focusing on breast, lung, and colon cancer. Using the Twitter application programming interface, we collected tweets containing keywords of the three cancers type in August-September 2022. The accounts were categorized into seven types: Survivor, Patient's family, Healthcare provider, Public organization, Private organization, News, and Other according to account name and texts. We analyzed the sources of the top 50 most liked and retweeted tweets. Out of 7753 identified tweets, breast cancer represented the majority (62.8%), followed by lung cancer (20.8%) and colon cancer (16.3%). Tweets came from 4976 accounts. Account types varied depending on the cancer type, with breast cancer topics more frequently from Survivor (16.0%) and lung cancer from Patient's family (16.3%). Healthcare provider and Public organization had minimal representation across three cancer types. The trends in the top 50 tweets mirrored the distribution of accounts for each cancer type. Breast cancer-related tweets had the highest frequency. There were few from public organizations. These findings emphasize the need to consider the characteristics of cancer-related information sources when sharing and gathering information on social media.
    MeSH term(s) Humans ; Female ; Social Media ; Japan/epidemiology ; Colonic Neoplasms/epidemiology ; Breast Neoplasms/epidemiology ; Lung Neoplasms/epidemiology ; Lung ; Demography
    Language English
    Publishing date 2024-03-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-024-56679-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Fact-Checking Cancer Information on Social Media in Japan: Retrospective Study Using Twitter.

    Kureyama, Nari / Terada, Mitsuo / Kusudo, Maho / Nozawa, Kazuki / Wanifuchi-Endo, Yumi / Fujita, Takashi / Asano, Tomoko / Kato, Akiko / Mori, Makiko / Horisawa, Nanae / Toyama, Tatsuya

    JMIR formative research

    2023  Volume 7, Page(s) e49452

    Abstract: Background: The widespread use of social media has made it easier for patients to access cancer information. However, a large amount of misinformation and harmful information that could negatively impact patients' decision-making is also disseminated on ...

    Abstract Background: The widespread use of social media has made it easier for patients to access cancer information. However, a large amount of misinformation and harmful information that could negatively impact patients' decision-making is also disseminated on social media platforms.
    Objective: We aimed to determine the actual amount of misinformation and harmful information as well as trends in the dissemination of cancer-related information on Twitter, a representative social media platform. Our findings can support decision-making among Japanese patients with cancer.
    Methods: Using the Twitter app programming interface, we extracted tweets containing the term "cancer" in Japanese that were posted between August and September of 2022. The eligibility criteria were the cancer-related tweets with the following information: (1) reference to the occurrence or prognosis of cancer, (2) recommendation or nonrecommendation of actions, (3) reference to the course of cancer treatment or adverse events, (4) results of cancer research, and (5) other cancer-related knowledge and information. Finally, we selected the top 100 tweets with the highest number of "likes." For each tweet, 2 independent reviewers evaluated whether the information was factual or misinformation, and whether it was harmful or safe with the reasons for the decisions on the misinformation and harmful tweets. Additionally, we examined the frequency of information dissemination using the number of retweets for the top 100 tweets and investigated trends in the dissemination of information.
    Results: The extracted tweets totaled 69,875. Of the top 100 cancer-related tweets with the most "likes" that met the eligibility criteria, 44 (44%) contained misinformation, 31 (31%) contained harmful information, and 30 (30%) contained both misinformation and harmful information. Misinformation was described as Unproven (29/94, 40.4%), Disproven (19/94, 20.2%), Inappropriate application (4/94, 4.3%), Strength of evidence mischaracterized (14/94, 14.9%), Misleading (18/94, 18%), and Other misinformation (1/94, 1.1%). Harmful action was described as Harmful action (9/59, 15.2%), Harmful inaction (43/59, 72.9%), Harmful interactions (3/59, 5.1%), Economic harm (3/59, 5.1%), and Other harmful information (1/59, 1.7%). Harmful information was liked more often than safe information (median 95, IQR 43-1919 vs 75.0 IQR 43-10,747; P=.04). The median number of retweets for the leading 100 tweets was 13.5 (IQR 0-2197). Misinformation was retweeted significantly more often than factual information (median 29.0, IQR 0-502 vs 7.5, IQR 0-2197; P=.01); harmful information was also retweeted significantly more often than safe information (median 35.0, IQR 0-502 vs 8.0, IQR 0-2197; P=.002).
    Conclusions: It is evident that there is a prevalence of misinformation and harmful information related to cancer on Twitter in Japan and it is crucial to increase health literacy and awareness regarding this issue. Furthermore, we believe that it is important for government agencies and health care professionals to continue providing accurate medical information to support patients and their families in making informed decisions.
    Language English
    Publishing date 2023-09-06
    Publishing country Canada
    Document type Journal Article
    ISSN 2561-326X
    ISSN (online) 2561-326X
    DOI 10.2196/49452
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article: Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy.

    Takatsuka, Daiki / Yoshimura, Akiyo / Sawaki, Masataka / Hattori, Masaya / Kotani, Haruru / Kataoka, Ayumi / Horisawa, Nanae / Ozaki, Yuri / Endo, Yuka / Nozawa, Kazuki / Iwata, Hiroji

    Journal of breast cancer

    2023  Volume 26, Issue 2, Page(s) 117–125

    Abstract: Purpose: Fine-needle aspiration cytology (FNAC) of axillary lymph nodes (AxLNs) is performed to diagnose nodal metastasis in patients with breast cancer. Although the sensitivity of ultrasound-guided FNAC for identifying AxLN metastasis is in the range ... ...

    Abstract Purpose: Fine-needle aspiration cytology (FNAC) of axillary lymph nodes (AxLNs) is performed to diagnose nodal metastasis in patients with breast cancer. Although the sensitivity of ultrasound-guided FNAC for identifying AxLN metastasis is in the range of 36%-99%, whether sentinel lymph node biopsy (SLNB) should be performed for neoadjuvant chemotherapy (NAC) patients with negative FNAC results is uncertain. This study aimed to determine the role of FNAC before NAC in the evaluation and management of AxLN in early breast cancer patients.
    Methods: We retrospectively analyzed 3,810 clinically node-negative (a lymph node with no clinical metastasis without FNAC or radiological suspicion of metastasis with negative FNAC results) patients with breast cancer who underwent SLNB between 2008 and 2019. We compared the positivity rate of sentinel lymph nodes (SLNs) between patients who received and those who did not receive NAC with negative FNAC results or without FNAC and axillary recurrence rate in the neoadjuvant group with negative SLNB results.
    Results: In the non-neoadjuvant (primary surgery) group, the positivity rate of SLNs in patients with negative FNAC results was higher than that in patients without FNAC (33.2% vs. 12.9%;
    Conclusion: The false-negative rate for FNAC in the primary surgery group was high; however, SLNB was the proper axillary staging procedure for NAC patients who have clinically suspicious AxLN metastases on radiologic examination but negative FNAC results.
    Language English
    Publishing date 2023-03-17
    Publishing country Korea (South)
    Document type Journal Article
    ZDB-ID 2559753-X
    ISSN 2092-9900 ; 1738-6756
    ISSN (online) 2092-9900
    ISSN 1738-6756
    DOI 10.4048/jbc.2023.26.e13
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6866: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy may Predict Pathological Complete Response with High Accuracy: Results from a Phase II Trial.

    Kataoka, Ayumi / Sawaki, Masataka / Horisawa, Nanae / Kotani, Haruru / Yoshimura, Akiyo / Hattori, Masaya / Adachi, Yayoi / Sugino, Kayoko / Endo, Yuka / Ozaki, Yuri / Sasaki, Eiichi / Hosoda, Waki / Iwata, Hiroji

    Annals of surgical oncology

    2023  Volume 30, Issue 6, Page(s) 3224–3232

    Abstract: Background: It is difficult to determine pathological complete response (pCR) before surgery in clinical complete response (cCR) cases by imaging alone. We designed a prospective study to evaluate whether a breast tissue marker placed in a tumor before ... ...

    Abstract Background: It is difficult to determine pathological complete response (pCR) before surgery in clinical complete response (cCR) cases by imaging alone. We designed a prospective study to evaluate whether a breast tissue marker placed in a tumor before neoadjuvant chemotherapy (NAC) can predict a pCR, possibly removing the need for surgery.
    Methods: We recruited patients with primary invasive breast cancer assigned to undergo curative surgery and possible NAC. A breast marker (UltraClip
    Results: A total of 102 patients were enrolled. Patients were categorized by cancer stage and subtypes. Seventy-two patients (70.6%) received standard NAC; 23 (34.3%) attained cCR, of whom pCR was obtained in 12 (52.2%). The probability of no cancer in the marker's location but cancer in the removed specimens was 4.3% (95% confidence interval, 0.1-21.9). The false-negative rate was 9.1% (1/11), and the negative predictive value was 92.3% (12/13). In only one case, no cancer was found in the marker's location, but cancer cells were present in the removed specimen.
    Conclusions: The absence of cancer in the location of a breast tissue marker after NAC predicted pCR with high accuracy. Therefore, the rebiopsy of a marker's location might mean surgery is unnecessary.
    MeSH term(s) Humans ; Female ; Neoadjuvant Therapy/methods ; Prospective Studies ; Breast/pathology ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Predictive Value of Tests ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Retrospective Studies ; Chemotherapy, Adjuvant
    Language English
    Publishing date 2023-02-08
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-023-13199-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4042: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Impact of Tumor Progression on Survival During Neoadjuvant Chemotherapy in Breast Cancer: A Cohort Study.

    Nozawa, Kazuki / Takatsuka, Daiki / Endo, Yuka / Horisawa, Nanae / Ozaki, Yuri / Kataoka, Ayumi / Kotani, Haruru / Yoshimura, Akiyo / Hattori, Masaya / Sawaki, Masataka / Iwata, Hiroji

    Anticancer research

    2022  Volume 42, Issue 7, Page(s) 3735–3742

    Abstract: Background/aim: Few patients with breast cancer experience tumor progression during neoadjuvant systemic therapy (NST), but their poor outcome is similar to that of patients who fail to achieve a pathological complete response (pCR). No previous reports ...

    Abstract Background/aim: Few patients with breast cancer experience tumor progression during neoadjuvant systemic therapy (NST), but their poor outcome is similar to that of patients who fail to achieve a pathological complete response (pCR). No previous reports have compared patients with pCR, non-pCR, and progression during NST to determine the survival outcomes.
    Patients and methods: This retrospective chart review of patients with stage I-III breast cancer was conducted between January 2001 and December 2018. pCR was defined as no invasive cancer or in situ residuals in the breast and lymph nodes (ypT0 ypN0). Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier methods.
    Results: Of the 595 patients who received NST, 167 (28.1%) had pCR (pCR group), 404 (67.9%) did not attain pCR (non-pCR group), and 24 (4.0%) experienced tumor progression during NST (PD group). The median DFS was 6.0 months, 154.0 months, and not reached in the PD, non-pCR, and pCR groups, respectively. The PD group had significantly shorter DFS than patients without tumor progression in the pCR and non-pCR groups [hazard ratio (HR)=13.0, 95%CI=8.1-21.0, p<0.01]. The median OS was 13.6 months (95%CI=10.4-35.5) in the PD group and was not reached in the pCR and non-pCR (non-PD) groups. The OS was significantly poorer in the PD group than in the non-PD groups (HR=15.8, 95%CI=9.2-27.1, p<0.01).
    Conclusion: The PD group had the poorest survival outcome even after recurrence, thus warranting new treatment strategies.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/pathology ; Cohort Studies ; Female ; Humans ; Neoadjuvant Therapy/methods ; Retrospective Studies
    Language English
    Publishing date 2022-07-05
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    DOI 10.21873/anticanres.15863
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use.

    Endo, Yuka / Yoshimura, Akiyo / Sawaki, Masataka / Hattori, Masaya / Kotani, Haruru / Kataoka, Ayumi / Horisawa, Nanae / Ozaki, Yuri / Nozawa, Kazuki / Takatsuka, Daiki / Isogai, Ayaka / Iwata, Hiroji

    Journal of breast cancer

    2022  Volume 25, Issue 4, Page(s) 296–306

    Abstract: Purpose: Safely postponing the use of chemotherapy is important for quality of life maintenance in patients with hormone receptor-positive advanced breast cancer. In previous studies, a combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) ...

    Abstract Purpose: Safely postponing the use of chemotherapy is important for quality of life maintenance in patients with hormone receptor-positive advanced breast cancer. In previous studies, a combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) and fulvestrant prolonged the time to chemotherapy (TTC). In this study, we used real-world data to evaluate TTC in the context of CDK4/6i therapy.
    Methods: We performed a retrospective chart review of women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated at the Aichi Cancer Center Hospital. The patients were categorized into having received CDK4/6i therapy first (n = 41), second (n = 33), and none at all (n = 67). The change in TTC among the groups was examined.
    Results: The median follow-up time was 13.8, 27.5, and 30.3 months in the CDK4/6i (first), CDK4/6i (second), and non-CDK4/6i groups, respectively. The median progression-free survival (PFS) with first-line therapy for metastasis was 30.0, 11.9, and 13.0 months, respectively (CDK4/6i [first] vs. non-CDK4/6i;
    Conclusion: Although PFS was significantly longer in the CDK4/6i (first) group than in the non-CDK4/6i group, TTC did not significantly differ among the three groups in real-world data. The non-CDK4/6i group showed a long TTC in patients with late recurrence and low risk at the primary lesion site, who benefited greatly from hormone monotherapy.
    Language English
    Publishing date 2022-08-28
    Publishing country Korea (South)
    Document type Journal Article
    ZDB-ID 2559753-X
    ISSN 2092-9900 ; 1738-6756
    ISSN (online) 2092-9900
    ISSN 1738-6756
    DOI 10.4048/jbc.2022.25.e34
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6866: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Satisfaction survey on a preoperative explanation method using three-dimensional breast imaging for breast cancer patients considering breast-conserving surgery.

    Ozaki, Yuri / Kotani, Haruru / Adachi, Yayoi / Sawaki, Masataka / Hattori, Masaya / Yoshimura, Akiyo / Kataoka, Ayumi / Nozawa, Kazuki / Sugino, Kayoko / Horisawa, Nanae / Endo, Yuka / Takatsuka, Daiki / Isogai, Ayaka / Iwata, Hiroji

    Surgery today

    2022  Volume 53, Issue 4, Page(s) 476–482

    Abstract: Purpose: Although one of the essential factors in surgical shared decision-making is the body image, the breast morphology after breast-conserving surgery is particularly difficult to explain in a uniform manner due to large individual differences.: ... ...

    Abstract Purpose: Although one of the essential factors in surgical shared decision-making is the body image, the breast morphology after breast-conserving surgery is particularly difficult to explain in a uniform manner due to large individual differences.
    Methods: Patients with breast cancer eligible for breast-conserving surgery (BCS) were recruited between June 2020 and October 2021. We surveyed the patients' satisfaction with our method of explaining the likely breast morphology after BCS using three-dimensional (3D) breast imaging in the form of a questionnaire.
    Results: A total of 162 patients were enrolled, and 137 (84.6%) answered the questionnaire. One hundred and sixteen patients (84.6%) answered that they were very satisfied or satisfied with our explanation method, and 100 (73.0%) patients were very satisfied or satisfied with the 3D breast imaging. Some patients answered that 3D breast imaging helped them prepare for BCS, or on the contrary, made them choose mastectomy with breast reconstruction because the deformation likely with BCS was considered unacceptable. Only a few patients who underwent BCS felt that their postoperative morphology was more deformed than the preoperatively imagined one.
    Conclusion: Our results suggest that our preoperative explanation method using 3D breast imaging was useful for shared decision-making.
    MeSH term(s) Humans ; Female ; Breast Neoplasms/diagnostic imaging ; Breast Neoplasms/surgery ; Mastectomy, Segmental/methods ; Mastectomy ; Patient Satisfaction ; Surveys and Questionnaires ; Personal Satisfaction
    Language English
    Publishing date 2022-09-21
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 1115435-4
    ISSN 1436-2813 ; 0941-1291
    ISSN (online) 1436-2813
    ISSN 0941-1291
    DOI 10.1007/s00595-022-02592-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 1077: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials.

    Nozawa, Kazuki / Takatsuka, Daiki / Endo, Yuka / Horisawa, Nanae / Ozaki, Yuri / Kataoka, Ayumi / Kotani, Haruru / Yoshimura, Akiyo / Hattori, Masaya / Sawaki, Masataka / Iwata, Hiroji

    Critical reviews in oncology/hematology

    2022  Volume 174, Page(s) 103703

    Abstract: Purpose: This study aimed to determine interstitial lung disease (ILD) incidences in patients receiving cancer drug therapies with or without bevacizumab treatment.: Methods: Systematic searches of PubMed, Embase, and Cochrane Library were conducted ... ...

    Abstract Purpose: This study aimed to determine interstitial lung disease (ILD) incidences in patients receiving cancer drug therapies with or without bevacizumab treatment.
    Methods: Systematic searches of PubMed, Embase, and Cochrane Library were conducted in January 2021. The main inclusion criteria were randomized clinical trials that compared bevacizumab with standard treatment in patients with solid tumors. Cochrane Collaboration's Tool was used for assessing risk-of-bias.
    Results: Thirteen records involving 7201 patients were included in the meta-analysis. There were 42 ILD events in bevacizumab groups and 72 in control groups. In bevacizumab groups, the odds ratio for ILD was 0.62 (95% CI 0.42-0.92; p = 0.02), which was a significantly lower incidence than the control. This tendency was shown in targeted therapy groups but not in the cytotoxic agent groups.
    Conclusion: Our data suggest that bevacizumab may reduce the incidence of ILD.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Bevacizumab/adverse effects ; Humans ; Lung Diseases, Interstitial/chemically induced ; Lung Diseases, Interstitial/epidemiology ; Neoplasms/chemically induced ; Neoplasms/complications ; Neoplasms/drug therapy ; Randomized Controlled Trials as Topic
    Chemical Substances Antineoplastic Agents ; Bevacizumab (2S9ZZM9Q9V)
    Language English
    Publishing date 2022-05-06
    Publishing country Netherlands
    Document type Journal Article ; Meta-Analysis ; Review ; Systematic Review
    ZDB-ID 605680-5
    ISSN 1879-0461 ; 0737-9587 ; 1040-8428
    ISSN (online) 1879-0461
    ISSN 0737-9587 ; 1040-8428
    DOI 10.1016/j.critrevonc.2022.103703
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1931: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis.

    Takatsuka, Daiki / Sawaki, Masataka / Hattori, Masaya / Yoshimura, Akiyo / Kotani, Haruru / Kataoka, Ayumi / Horisawa, Nanae / Ozaki, Yuri / Endo, Yuka / Nozawa, Kazuki / Iwata, Hiroji

    Asia-Pacific journal of clinical oncology

    2022  Volume 19, Issue 5, Page(s) e175–e182

    Abstract: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have been approved for breast cancer (BC) treatment. Several trials suggested that arthralgia was reduced in patients treated with ET plus CDK4/6i compared with ... ...

    Abstract Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have been approved for breast cancer (BC) treatment. Several trials suggested that arthralgia was reduced in patients treated with ET plus CDK4/6i compared with that in those with ET-alone. We aimed to compare arthralgia rates in BC patients treated with/without CDK4/6i. We reviewed randomized controlled phase II/III trials investigating CDK4/6i with ET in hormone receptor-positive and epidermal growth factor 2-negative BC. Publications were retrieved from PubMed from January 2014 to April 2021. We compared arthralgia rates between patients who were administered ET plus CDK4/6i (CDK4/6i group) and those treated with ET-alone (control group). We reviewed 12 trials that reported data on adverse effects for arthralgia. These trials included 17,440 patients (9255 in the CDK4/6i group and 8185 in the control group). The arthralgia rate in the CDK4/6i group was significantly lower than that in the control group (27.6% vs. 34.8%, p < .001), especially in early BC (28.8% vs. 37.3%, p < .001). These suggested that the arthralgia rate in patients treated with ET plus CDK4/6i was lower than that in patients treated with ET-alone and that CDK4/6i may decrease the arthralgia rate in BC patients treated with ET, especially in early BC.
    MeSH term(s) Humans ; Female ; Breast Neoplasms/metabolism ; Cyclin-Dependent Kinase 4 ; Protein Kinase Inhibitors/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Clinical Trials, Phase II as Topic ; Randomized Controlled Trials as Topic
    Chemical Substances Cyclin-Dependent Kinase 4 (EC 2.7.11.22) ; Protein Kinase Inhibitors
    Language English
    Publishing date 2022-09-09
    Publishing country Australia
    Document type Meta-Analysis ; Systematic Review ; Journal Article ; Review
    ZDB-ID 2187409-8
    ISSN 1743-7563 ; 1743-7555
    ISSN (online) 1743-7563
    ISSN 1743-7555
    DOI 10.1111/ajco.13840
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial.

    Kotani, Haruru / Terada, Mitsuo / Mori, Makiko / Horisawa, Nanae / Sugino, Kayoko / Kataoka, Ayumi / Adachi, Yayoi / Gondou, Naomi / Yoshimura, Akiyo / Hattori, Masaya / Sawaki, Masataka / Takahata, Chihoko / Kobara, Makiko / Iwata, Hiroji

    BMC cancer

    2021  Volume 21, Issue 1, Page(s) 548

    Abstract: Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of paclitaxel (PTX). There is no known prophylactic measure, although there are some reports of prevention with compression therapy using surgical gloves. On ... ...

    Abstract Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of paclitaxel (PTX). There is no known prophylactic measure, although there are some reports of prevention with compression therapy using surgical gloves. On account of its predominantly subjective symptoms, it is difficult to exclude bias when assessing for CIPN. In this study, we assessed the effectiveness of the same procedure for the prevention of paclitaxel-induced PN based on a double-blind study design.
    Methods: The patients with early and recurrent breast cancer (with no prior PTX exposure) initiating weekly chemotherapy with PTX 80 mg/m
    Results: Between July 2017 and November 2018, 56 patients were enrolled and 49 patients were evaluated. Overall, Grade ≥ 2 PN (sensory) was observed in 30.6 and 36.7% in the study and control sides, respectively (McNemar p = 0.25). PN (motor) was observed in 4.1 and 6.1% in the study and control sides, respectively (McNemar p = 1.0).
    Conclusion: Surgical glove compression therapy showed no statistically significant effect on the incidence of PTX-induced PN.
    Trial registrations: This study was registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry managed by the National University Hospital Council of Japan ( UMIN000027944 ). Registered 26 June 2017.
    MeSH term(s) Adult ; Aged ; Breast Neoplasms/drug therapy ; Compression Bandages ; Double-Blind Method ; Female ; Gloves, Surgical ; Humans ; Middle Aged ; Paclitaxel/adverse effects ; Peripheral Nervous System Diseases/chemically induced ; Peripheral Nervous System Diseases/prevention & control ; Young Adult
    Chemical Substances Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2021-05-13
    Publishing country England
    Document type Clinical Trial, Phase II ; Journal Article
    ISSN 1471-2407
    ISSN (online) 1471-2407
    DOI 10.1186/s12885-021-08240-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top